Saturday, October 07, 2017 4:35:14 PM
1. We can expect results from two first generation ImPACT HS-110 NSCLC trials this fall. We should see the final Phase II results from the HS-110 plus low dose cyclophosphamide 4th line trial. We can also expect interim results from the open label Phase II HS-110 plus Opdivo NSCLC second line trial. We may hear top-line results at any time-but I would expect more detailed scientific data to be presented at the World Conference on Lung Cancer October 16-18 and at the Society for Immunotherapy of Cancer meeting November 8-12. Potential partners will be interested as phase II is frequently a "sweet spot" for partnering.
2. The second generation ComPACT technology(HS-110 plus OX40)has produced very impressive pre-clinical trial results. It is ready to enter the clinic in NSCLC and "several other" cancers. I expect this will happen with a partner.
3. Although the company is no longer pursuing the HS-410 bladder cancer program- the patients are still being monitored. So far interim analysis indicate that the 2 year results will show a very significant benefit over the BCG SOC. This indication could also be partnered in the future as the solo BCG treatment benefit drops off dramatically in years two and three. Dr. Gary Steinberg(PI) in an interview suggested that the next step might combine HS-410 + BCG + a checkpoint inhibitor. HS-410 produced a clear immune response not seen with BCG alone.
4. The acquisition of an 80% interest in Pelican brought in over $15 million in grants. This will fund a 70 patient Phase I trial to see how PTX-25 might benefit lung, lymphoma, prostate, pancreatic, and ovarian cancers. We have seen good progress and should expect more news from Pelican this fall.
5. The creation of the 100% Zolovax subsidiary was followed by the award of a $1 million grant to develop a Zika vaccine. Preclinical animal data can be expected soon. Other infectious diseases of interest include HIV, West Nile virus, Dengue and yellow fever. I would expect that any successful vaccines will be developed through further grants and partnerships.
6. Japanese pharma giant Takeda's recent collaboration with Heat's spin-off Shattuck Labs was signalled several months earlier when Shattuck announced that an "international pharma" had taken a substantial position in a cash raise. At that time Heat's CEO said that since Shattucks' technology was licenced from Heat, Heat would benefit in the future from milestone and royalty payments. In addition to those benefits it is clear that Takeda would have done their due diligence on Heat! When the two ImPACT trial results are released this fall-Takeda along with half a dozen checkpoint inhibitor pharmas will be interested IMO.
7. The recent announcement of a Type C meeting with the FDA to seek quidance for the registration pathway for the HS-110 plus Opdivo combination is very significant. I believe that potential partners will be very interested in the outcome! This meeting will happen this fall.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent NHWK News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/07/2024 04:15:18 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/03/2024 08:00:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/03/2024 11:18:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2024 12:00:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2024 12:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2024 12:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 09:00:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:52:07 PM
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM